<DOC>
	<DOCNO>NCT00390650</DOCNO>
	<brief_summary>The primary objective evaluate efficacy 100 mg dose saredutant compare placebo patient generalize anxiety disorder . The secondary objective evaluate efficacy saredutant disability quality life patient generalize anxiety disorder , evaluate blood level saredutant .</brief_summary>
	<brief_title>A North-American Eight-week Study Evaluate Efficacy Safety Saredutant Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Diagnosis generalize anxiety disorder define Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) criterion confirm Mini International Neuropsychiatric Interview ( MINI ) Plus Generalized Anxiety Disorder module . Total score le 22 HAMA . MontgomeryAsberg Depression Rating Scale ( MADRS ) total score great 18 . Patients current history ( within 6 month ) major depressive disorder history presence bipolar disorder psychotic disorder . Patients alcohol dependence abuse substance dependence abuse past 12 month except nicotine caffeine dependence . Patients use follow prior entry Acute Phase : antipsychotic within 3 month , antidepressant include Monoamine Oxidase Inhibitors ( MAOIs ) within 1 month , anxiolytic within 2 week , moodstabilizer ( lithium , anticonvulsant ) within 1 month , and/or high dose prolong benzodiazepine ( continuous use 3 month prior admission ) use . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>clinical trial</keyword>
</DOC>